RxDoctor Payments Data

Brendan Burke, MD

Obstetrics & Gynecology · Chevy Chase, MDNPI 1588629380

Payments from drug & device makers

What this record shows

This record is dominated by grants: $5,000 of the $6,165 with a category attached, or 81.1%. Medtronic accounts for 81.1% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2024 at $5,070 and has fallen 97.0% since, to $153 in 2025. Among obstetrics & gynecology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,165in general payments, 2019–2025

Across 54 payments — averaging $114.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Pfizer$203
  • AbbVie$182
  • Therapeuticsmd, Inc.$150
  • Hologic Sales And Service, LLC$83
  • Renovia Inc$78
  • plus $468 from 15 others

What the payments were for

  • Grants$5,00081%
  • Food & beverage$1,07917%
  • Education$861%

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,165 in reported general payments places this provider in the 90th percentile of 842 obstetrics & gynecology providers in Maryland.

See all obstetrics & gynecology providers in Maryland

Medicare billing

Part B allowed, 2024
$42,056
Medicare patients
342
Services billed
785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated59$29,094
PremproEstrogen,con/M-Progest Acet21$14,788
Estradiol194$14,459
EstringEstradiol21$11,128
YuvafemEstradiol15$2,350
ProgesteroneProgesterone, Micronized44$1,827
ValacyclovirValacyclovir Hcl22$830
Metronidazole11$472
Medroxyprogesterone Acetate24$455
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$160
Fluconazole27$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin, Prempro, Estring$203$55,009101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 842 obstetrics & gynecology providers in Maryland.

Other obstetrics & gynecology in Chevy Chase

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →